REFERENCES
1. Moradi M, Esmaeili S, Shoar S, Safari S. Use of oxycodone in pain management. Anesth Pain Med. 2012;1:262-4.
2. Kibaly C, Alderete JA, Liu SH, et al. Oxycodone in the opioid epidemic: high ‘liking’, ‘wanting’, and abuse liability. Cell Mol Neurobiol. 2021;41:899-926.
3. Giovannini E, Bonasoni MP, Pascali JP, et al. Fetal and infant effects of maternal opioid use during pregnancy: a literature review including clinical, toxicological, pharmacogenomic, and epigenetic aspects for forensic evaluation. Children. 2024;11:278.
4. Radhakrishna U, Radhakrishnan R, Uppala LV, et al. Prenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome. Front Pain Res. 2025;6:1497801.
5. Yen E, Davis JM. The immediate and long-term effects of prenatal opioid exposure. Front Pediatr. 2022;10:1039055.
6. Feng Y, Lau S, Chen Q, et al. Normotensive placental extracellular vesicles provide long-term protection against hypertension and cardiovascular disease. Am J Obstet Gynecol. 2024;231:350.e1-24.
7. Darbinian N, Merabova N, Tatevosian G, et al. Prenatal opioid and alcohol exposures: association with altered placental serotonin transporter structure and/or expression. Int J Mol Sci. 2024;25:11570.
8. Jeyarajah MJ, Patterson VS, Jaju Bhattad G, Zhao L, Whitehead SN, Renaud SJ. Placental extracellular vesicles promote cardiomyocyte maturation and fetal heart development. Commun Biol. 2024;7:1254.
9. Broussard CS, Rasmussen SA, Reefhuis J, et al.; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204:314.e1-11.
10. Esposito DB, Bateman B, Werler M, et al. Ischemic placental disease, preterm delivery, and their association with opioid use during pregnancy. Am J Epidemiol. 2022;191:759-68.
11. Green MT, Martin RE, Kinkade JA, et al. Maternal oxycodone treatment causes pathophysiological changes in the mouse placenta. Placenta. 2020;100:96-110.
12. Ahmed N, Kassis A, Malone J, et al. Prenatal morphine exposure increases cardiovascular disease risk and programs neurogenic hypertension in the adult offspring. Hypertension. 2023;80:1283-96.
13. Odegaard KE, Schaal VL, Clark AR, et al. A holistic systems approach to characterize the impact of pre- and post-natal oxycodone exposure on neurodevelopment and behavior. Front Cell Dev Biol. 2020;8:619199.
14. Goetzl L, Thompson-Felix T, Darbinian N, et al. Novel biomarkers to assess in utero effects of maternal opioid use: first steps toward understanding short- and long-term neurodevelopmental sequelae. Genes Brain Behav. 2019;18:e12583.
15. Nguyen NM, Vellichirammal NN, Guda C, Pendyala G. Decoding the synaptic proteome with long-term exposure to midazolam during early development. Int J Mol Sci. 2022;23:4137.
16. Odegaard KE, Schaal VL, Clark AR, et al. Characterization of the intergenerational impact of in utero and postnatal oxycodone exposure. Transl Psychiatry. 2020;10:329.
17. Lyu Z, Kinkade JA, Bivens NJ, Roberts RM, Joshi T, Rosenfeld CS. Effects of oxycodone on placental lineages: Evidence from the transcriptome profile of mouse trophoblast giant cells. Proc Natl Acad Sci U S A. 2024;121:e2412349121.
18. Minakova E, Sarafinovska S, Mikati MO, et al. Ontogenetic oxycodone exposure affects early life communicative behaviors, sensorimotor reflexes, and weight trajectory in mice. Front Behav Neurosci. 2021;15:615798.
19. Flores A, Nguyen NM, Devanaboyina M, et al. Neurobehavioral characterization of perinatal oxycodone-exposed offspring in early adolescence. J Neuroimmune Pharmacol. 2024;19:29.
20. Chand S, Gowen A, Savine M, et al. A comprehensive study to delineate the role of an extracellular vesicle-associated microRNA-29a in chronic methamphetamine use disorder. J Extracell Vesicles. 2021;10:e12177.
21. Koul S, Schaal VL, Chand S, et al. Role of brain derived extracellular vesicles in decoding sex differences associated with nicotine self-administration. Cells. 2020;9:1883.
22. Nguyen NM, Meyer D, Meyer L, et al. Identification of YWHAH as a novel brain-derived extracellular vesicle marker post long-term midazolam exposure during early development. Cells. 2023;12:966.
23. Shahjin F, Guda RS, Schaal VL, et al. Brain-derived extracellular vesicle microRNA signatures associated with in utero and postnatal oxycodone exposure. Cells. 2019;9:21.
24. Kannan M, Singh S, Chemparathy DT, et al. HIV-1 Tat induced microglial EVs leads to neuronal synaptodendritic injury: microglia-neuron cross-talk in NeuroHIV. Extracell Vesicles Circ Nucl Acids. 2022;3:133-49.
25. Meyer D, Athota P, Gowen A, et al. Effect of combined methamphetamine and oxycodone use on the synaptic proteome in an in vitro model of polysubstance use. Genes. 2022;13:1816.
26. Nakahara A, Nair S, Ormazabal V, et al. Circulating placental extracellular vesicles and their potential roles during pregnancy. Ochsner J. 2020;20:439-45.
27. Sun Q, Chang H, Wang H, et al. Regulatory roles of extracellular vesicles in pregnancy complications. J Adv Res. 2025;78:363-75.
28. Dai H, Lu X. MGST1 alleviates the oxidative stress of trophoblast cells induced by hypoxia/reoxygenation and promotes cell proliferation, migration, and invasion by activating the PI3K/AKT/mTOR pathway. Open Med. 2022;17:2062-71.
29. Reimers A, Østby L, Stuen I, Sundby E. Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. Eur J Drug Metab Pharmacokinet. 2011;35:79-82.
30. Collier AC, Ganley NA, Tingle MD, et al. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol. 2002;63:409-19.
31. Kawase T, Ohki R, Shibata T, et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell. 2009;136:535-50.
32. Butelman ER, Goldstein RZ, Nwaneshiudu CA, et al. Neuroimmune mechanisms of opioid use disorder and recovery: translatability to human studies, and future research directions. Neuroscience. 2023;528:102-16.
33. Hansen SSK, Krautz R, Rago D, et al. Pulmonary maternal immune activation does not cross the placenta but leads to fetal metabolic adaptation. Nat Commun. 2024;15:4711.
34. Giussani DA, Camm EJ, Niu Y, et al. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. PLoS One. 2012;7:e31017.
35. Aljunaidy MM, Morton JS, Cooke CM, Davidge ST. Prenatal hypoxia and placental oxidative stress: linkages to developmental origins of cardiovascular disease. Am J Physiol Regul Integr Comp Physiol. 2017;313:R395-9.
36. Julian CG, Houck JA, Fallahi S, et al. Altered placental ion channel gene expression in preeclamptic high-altitude pregnancies. Physiol Genomics. 2023;55:357-67.
37. Chen L, Xiu Y, Wu Q, et al. Maternal serum Lamin A is a potential biomarker that can predict adverse pregnancy outcomes. EBioMedicine. 2022;77:103932.
38. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-32.
39. Santos MC, Birkenfeld L, Pham T, et al. Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts. Clin Sci. 2025;139:507-26.
40. Wang Y, Chen Q, Zhao M, Walton K, Harrison C, Nie G. Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signaling. J Clin Endocrinol Metab. 2017;102:3065-74.
41. Soncin F, Khater M, To C, et al. Comparative analysis of mouse and human placentae across gestation reveals species-specific regulators of placental development. Development. 2018;145:dev156273.
